Partnered-DEP® products - AZD0466

Starpharma’s DEP® platform can enhance the commercial and therapeutic value of a wide range of drugs, making it a highly valuable partnering technology


  • is a highly optimised nanomedicine formulation of Astra Zeneca cancer drug AZD4320
  • is currently in a phase 1 clinical trial (FDA IND)
  • is a Bcl2/xL inhibitor which has improved preclinical efficacy and therapeutic margin
  • has been described as a potentially “best-in-class” drug with a broad combination opportunity in solid and haematological tumours (blood cancers) due to its ability to target both Bcl2 and Bcl/xL 
  • is the subject of a US patent granted for DEP® -Bcl2/xL conjugates, giving protection until 2038 with potential for up to 5-year extension

The development of AZD0466, is being progressed under a multi-product license whereby Starpharma is eligible to receive development, launch and sales milestones of up to US$124 million, plus tiered royalties on net sales, and with all development costs funded by AstraZeneca.

The FDA has authorised an IND for AZD0466, and a phase 1 trial has commenced in CY19.

Starpharma’s commercial partnership with AstraZeneca includes a multiproduct DEP® licence, which currently involves the development and commercialisation of two novel AstraZeneca oncology compounds, with potential to add more. Starpharma also has a Development and Option agreement with AstraZeneca for a DEP® version of one of AstraZeneca’s major marketed oncology medicines.

1 Multiple preclinical studies have established improved efficacy, survival and safety with DEP®  with many different drugs; clinical trials underway.

For more information about Starpharma’s DEP® platform or to explore partnering opportunities, contact us at

Download related announcements below: